 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...172173174175176177178179180181182...208209» |
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Enrollment open: Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment (clinicaltrials.gov) - Jun 22, 2020
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting
- |||| AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=53, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- || SHR-1702 / Jiangsu Hengrui Pharma
New P1 trial, Monotherapy: A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 22, 2020
P1, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open: DAWNA-2: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Jun 22, 2020
P3, N=426, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: IMplus: Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 22, 2020
P2, N=32, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- ||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer (clinicaltrials.gov) - Jun 22, 2020
P1/2, N=82, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Clinical, P2 data, Journal: Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. (Pubmed Central) - Jun 19, 2020
Not yet recruiting --> Recruiting In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study. (Pubmed Central) - Jun 19, 2020
The present prospective observational study showed favorable effectiveness and safety of apatinib in real-world patients with advanced or metastatic GC in China. (A prospective, multi-center, non-intervention study of apatinib in the treatment of advanced gastric cancer-Trial Registry Number: ChiCTR-OPN-15006601).
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study. (Pubmed Central) - Jun 19, 2020
P=N/A
Patients with a smaller tumor size and extraskeletal myxoid chondrosarcoma subtype might benefit from this therapy more. Registered February 7, 2020, with clinicaltrials.gov: NCT04260113.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P1 trial: Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects (clinicaltrials.gov) - Jun 18, 2020
P1, N=18, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial completion date: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Jun 18, 2020
P3, N=240, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Registered February 7, 2020, with clinicaltrials.gov: NCT04260113. Trial completion date: Dec 2019 --> Mar 2021
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. (Pubmed Central) - Jun 18, 2020
P2
Apatinib exhibited efficacy and an acceptable safety profile in previously heavily-treated ES-SCLC patients. Further exploration of apatinib in phase III trials is warranted.
- |||| plinabulin (BPI 2358) / BeyondSpring
Clinical: The topline results of the prespecified interim analysis demonstrated efficacy in preventing grade 4 neutropenia with the addition of plinabulin. @BlayneyDouglas https://t.co/Lj0lTEkx92 (Twitter) - Jun 18, 2020
- || AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma (clinicaltrials.gov) - Jun 17, 2020
P2, N=97, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Further exploration of apatinib in phase III trials is warranted. Not yet recruiting --> Active, not recruiting
- ||| SHR-1222 / Jiangsu Hengrui Pharma
New P1 trial: A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients (clinicaltrials.gov) - Jun 16, 2020
P1, N=100, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
Clinical: The combination of plinabulin and pegfilgrastim (Neulasta) showed a significant enhancement in the rate of grade 4 #neutropenia prevention compared with pegfilgrastim alone in patients undergoing chemotherapy. @BlayneyDouglas https://t.co/XBhrS65MX5 (Twitter) - Jun 16, 2020
- || SHR-1222 / Jiangsu Hengrui Pharma
Trial completion: The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects (clinicaltrials.gov) - Jun 16, 2020
P1, N=50, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: ACCORD: Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (clinicaltrials.gov) - Jun 15, 2020
P2, N=92, Active, not recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
Clinical: Plinabulin/Pegfilgrastim Combo Shows Efficacy in Prevention of Severe Neutropenia @BlayneyDouglas @StanfordMed https://t.co/UQOE8XBCSa (Twitter) - Jun 15, 2020
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Biomarker, Clinical, Journal, Real-World Evidence, Tumor Mutational Burden: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis. (Pubmed Central) - Jun 13, 2020
Pyrotinib seems to be a feasible strategy both in combination of chemotherapeutic drugs or as a replacement of lapatinib if diseases progressed. TMB could be a potential predictor for evaluating pyrotinib's effectiveness in HER2-positive MBC.
- | AiTan (rivoceranib) / HLB Bio Group, cisplatin / Generic mfg.
Journal: Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway. (Pubmed Central) - Jun 11, 2020
Our study indicates that apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer by deactivating the Akt/β-catenin pathway. These findings provide a theoretical foundation for using apatinib as an effective therapeutic drug for esophageal cancer.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC (clinicaltrials.gov) - Jun 11, 2020
P2, N=59, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
- ||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2020
P1, N=74, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jun 11, 2020
P3, N=390, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
New P1 trial: A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. (clinicaltrials.gov) - Jun 11, 2020
P1, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group, gefitinib / Generic mfg.
Clinical, Journal: Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. (Pubmed Central) - Jun 9, 2020
P3
Apatinib (500 mg) plus gefitinib (250 mg) showed a tolerable safety profile and encouraging antitumor activity for advanced EGFR-mutant NSCLC in the first-line setting. Phase III trials of apatinib (500 mg) plus gefitinib (250 mg) are warranted.
- |||| AiRuiKa (camrelizumab) / Incyte
Clinical: ESCORT study. @CathyEngMD @rachnatshroff @GIcancerDoc @SWOG Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT) https://t.co/rEsWInBeEM (Twitter) - Jun 9, 2020
- ||||||| AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - Jun 9, 2020
P3, N=419, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase III trials of apatinib (500 mg) plus gefitinib (250 mg) are warranted. Recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis?SHR-1210-HLJ-009? (clinicaltrials.gov) - Jun 8, 2020
P=N/A, N=34, Not yet recruiting, Sponsor: Yanqiao Zhang
- | New P2 trial: PLATFORM Study of Precision Medicine for Rare Tumors (clinicaltrials.gov) - Jun 8, 2020
P2, N=624, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P1 trial: Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects (clinicaltrials.gov) - Jun 8, 2020
P1, N=18, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / Incyte, decitabine / Generic mfg.
Journal: Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. (Pubmed Central) - Jun 8, 2020
CR rate in patients with relapsed/refractory cHL who were clinically naïve to PD-1 blockade was significantly higher with decitabine plus camrelizumab than with camrelizumab alone. Decitabine plus camrelizumab may reverse resistance to PD-1 inhibitors in patients with relapsed/refractory cHL.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal, Real-World Evidence: Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study. (Pubmed Central) - Jun 8, 2020
Apatinib produced moderate improvements in progression-free survival in patients with platinum-resistant epithelial ovarian cancer both as maintenance therapy following chemotherapy and as single-agent salvage therapy. Our study suggests that apatinib may be effective for women with platinum-resistant recurrent epithelial ovarian cancer.
- |||| SHR7280 / Jiangsu Hengrui Pharma
New P1/2 trial: The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis. (clinicaltrials.gov) - Jun 4, 2020
P1/2, N=166, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical, Retrospective data, Journal, Real-World Evidence: Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice (Pubmed Central) - Jun 4, 2020
Our study suggests that apatinib may be effective for women with platinum-resistant recurrent epithelial ovarian cancer. Pyrotinib based therapy is an effective treatment for patients with HER2 positive MBC, including patients with lapatinib treatment failure and brain metastasis, and the toxicities can be tolerated.
- |||| Clinical: TG-1801 is already (CD47/CD19) is already in clinical trials https://t.co/mAG9oCIA5d TG-1701 BTK inhibitor is in trial in Australia by @chanyooncheah Not to mention umbralisib ublituximab plus all combos. (Twitter) - Jun 4, 2020
- || SHR-1802 / Jiangsu Hengrui Pharma
New P1 trial, Metastases: A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours (clinicaltrials.gov) - Jun 3, 2020
P1, N=42, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
New P1 trial: A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function (clinicaltrials.gov) - Jun 3, 2020
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Jun 3, 2020
P2, N=48, Recruiting, Sponsor: Zhejiang Cancer Hospital
- || Tykerb (lapatinib) / Novartis, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, capecitabine / Generic mfg.
PHOEBE: pyrotinib o lapatinib con capecitabine en HER2+ avanzado -Pyrotinib mejoro supervivencia sin progresion vs lapatinib( 12.5 vs 6.8meses, HR 0.39), respuesta objetiva, duracion de respuesta. -Data no madura para supervivencia general. 14/x https://t.co/e1cNVFkLqg (Twitter) - Jun 2, 2020
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 1, 2020
P2, N=46, Not yet recruiting, Sponsor: Xin-Hua Xu
- |||||||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P3 trial: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib (clinicaltrials.gov) - May 31, 2020
P3, N=304, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, P2 data, Journal: Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. (Pubmed Central) - May 31, 2020
P2
We conclude that apatinib is effective and well tolerated in patients with advanced sarcoma. The development of hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorable prognosis, representing a novel finding in sarcoma patients.
- |||| Clinical: PHOEBE results: pyrotinib PFS significantly > lapatinib (12.5 vs 6.8 mo, p< .001, HR 0.39. OS immature but trending for pyrotinib. More diarrhea with pyrotinib. My thoughts: good data, and pyr better than lap, but very different pts. No T-DM1 or pertuzumab. #ASC020 #bcsm (Twitter) - May 30, 2020
- ||||| Tykerb (lapatinib) / Novartis, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical: PHOEBE trial from China randomized pts to Cape + lapatinib vs Cape + the pan-ErbB RTKi pyrotinib. All had prior trastuzumab and taxanes and/or anthracyclines & up to 2 prior CT for MBC. Primary endpoint was PFS, N = 267, and 1/4 were resistant to prior trastuzumab. #ASC020 #bcsm (Twitter) - May 30, 2020
- ||||| Tykerb (lapatinib) / Novartis, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, capecitabine / Generic mfg.
P3 data: PHOEBE phase III trial: pyrotinib or lapatinib plus capecitabine in HER2+ metastatic #breastcancer Pyrotinib improved PFS vs lapatinib( 12.5 vs 6.8m, HR 0.39), ⬆️ORR CBR DOR, OS data not mature yet. Grade3 diarrhea: 30% #ASCO20 #BCSM #OncoAlert (Twitter) - May 29, 2020
- | AiTan (rivoceranib) / HLB Bio Group
Journal: MicroRNA-106a-3p Induces Apatinib Resistance and Activates Janus-Activated Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) by Targeting the SOCS System in Gastric Cancer. (Pubmed Central) - May 29, 2020
CONCLUSIONS miR-106a-3p induces apatinib resistance and activates JAK2/STAT3 by targeting SOCS system in gastric cancer. miR-106a-3p/SOCS plays a potent role in gastric cancer cell resistance to apatinib.
- |||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Response duration meaningful here at 11 months for #pyrotinib. Median OS not reached in either arm. 📌more G3 diarrhea with pyrotinib (30.6 vs. 8.3%)...everything else pretty comparable. #ASCO20 #bcsm @OncoAlert (Twitter) - May 29, 2020
- |||| Tykerb (lapatinib) / Novartis, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Dr. Xu shows #PHOEBE results of ph III pyrotinib/cape vs. lapatinib/cape. 🧬 PFS 6.8 LC vs. 12.5 months PC, HR 0.39 🔎most common AE diarrhea (G3 30% vs. 8%) #ASCO20 #bcsm @OncoAlert (Twitter) - May 29, 2020
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, Combination therapy, Monotherapy: Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. (Pubmed Central) - May 28, 2020
Here, we represent preliminary evidence for the comparative safety and efficacy of existing anti-PD-1 agents with/without chemotherapy in RM-NPC, which indicated that camrelizumab has the least toxicity profile and merits future investigation. Our findings might provide insights into the future design of immunotherapy trials in RM-NPC.